Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Roche
Biotech
Ollin eyes phase 3 after topping Vabysmo in early-stage trial
Given the findings, the Texas-based biotech is now planning to launch global phase 3 studies this year.
Gabrielle Masson
Jan 8, 2026 3:20pm
Roche commits $100M to keep its GLP-1 Structure sound
Jan 6, 2026 10:21am
Addition Tx does the math and emerges from stealth with $100M
Dec 17, 2025 7:45am
Dealmaking flurry continues with Genentech-Caris cancer collab
Dec 16, 2025 11:00am
Roche links SERD to 30% breast cancer risk reduction in phase 3
Dec 10, 2025 8:15am
Paradigm snags $78M to revamp CRO space, inks deal with Flatiron
Dec 4, 2025 2:35pm
